Peak Bio, Inc. (PKBO)
OTCMKTS
· Delayed Price · Currency is USD
0.0225
0.00 (0.00%)
Inactive · Last trade price
on Nov 14, 2024
Peak Bio Employees
Peak Bio had 6 employees as of December 31, 2023. The number of employees decreased by 15 or -71.43% compared to the previous year.
Employees
6
Change (1Y)
-15
Growth (1Y)
-71.43%
Revenue / Employee
$12,532
Profits / Employee
-$554,013
Market Cap
520.31K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6 | -15 | -71.43% |
| Dec 31, 2022 | 21 | -9 | -30.00% |
| Dec 31, 2021 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sandoz Group AG | 22,633 |
| Telix Pharmaceuticals Limited | 234 |
| Elekta AB (publ) | 4,718 |
| Ryman Healthcare Limited | 7,700 |
| Verano Holdings Corp. | 3,900 |
| Vireo Growth Inc. | 490 |
| Medexus Pharmaceuticals Inc. | 82 |
Peak Bio News
- 3 months ago - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO - Accesswire
- 11 months ago - Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari - PRNewsWire
- 11 months ago - Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Up-listing to OTCQB Market - GlobeNewsWire
- 1 year ago - Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital - GlobeNewsWire